Objective: We investigated the effects of tirzepatide, an injectable GLP-1 receptor agonist, on blood glucose, biochemical data, home blood pressure, and arteriosclerosis indices after 12 months of administration in type 2 Diabetes with Hyperension. Design and method: Twenty-two patients with type 2 diabetes (mean age 64 years, BMI 27 kg/m2, 17 men; 10 patients added to existing treatment (group A) and 12 patients switched (5 switched from DPP4 inhibitors, 7 switched from other GLP-1 receptor agonists, group B) receiving diet and exercise therapy were administered tirzepatide at doses of 2.5 to 10 mg/day. Blood glucose, biochemical data, urinary protein, home blood pressure, baPWV, and central blood pressure were measured over the 12-month period. Results: Before and 12 months after administration, HbA1c decreased significantly (p<0.05) from 7.8±1.1 to 6.3±0.6% in all patients, from 7.9±1.2 to 6.2±0.6% in group A, and from 7.8±1.1 to 6.5±0.7% in group B. Overall, body weight decreased significantly (p<0.05) from 84.5±15.6 to 79.5±17.5 (-5.1±4.7 kg). Home blood pressure (mmHg): 127.8±11.1/75.4±10.0 to 118.2±9.6 Blood pressure significantly decreased from 115.1±12.8 to 112.5±12.6 (cSBP (mmHg)), and LDL-C, triglycerides, and liver function tended to improve. There were no clear changes in eGFR or uric acid before and after administration, but urinary protein (mg/g/Cr) significantly decreased from 2086.7±3756.0 to 622.4±1009.5. No hypoglycemia or obvious side effects were observed. Conclusions: These results suggest that tirzepatide may exhibit not only a blood glucose-lowering effect, but also antihypertensive and anti-atherosclerotic effects.
Toshio Yamagishi (Fri,) studied this question.